Literature DB >> 8403329

Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome.

M Rubart1, M L Pressler, H P Pride, D P Zipes.   

Abstract

BACKGROUND: Erythromycin is known to prolong ventricular repolarization and has been associated with the occurrence of torsades de pointes. In this study, we have investigated potential mechanisms in vivo and in vitro for induction of an acquired long QT syndrome by erythromycin. METHODS AND
RESULTS: Ventricular electrograms and endocardial monophasic action potentials were recorded in anesthetized open-chest dogs before and after administration of 40 to 120 mg/kg of erythromycin lactobionate. Conventional microelectrode techniques were used to record transmembrane action potentials in isolated dog Purkinje fibers and papillary muscles. Erythromycin at concentrations > 20 mg/L prolonged action potential duration. At higher concentrations (100 to 200 mg/L), erythromycin induced phase 2 and phase 3 early afterdepolarizations (EADs) both in vivo and in vitro. The effects of erythromycin on repolarization were more marked in Purkinje fibers than in papillary muscle. Pretreatment of Purkinje fibers with erythromycin antagonized the effects of dofetilide, a selective delayed-rectifier potassium channel (IK) blocker. Pretreatment with prazosin or tetrodotoxin had no effect on erythromycin-induced changes in action potential duration.
CONCLUSIONS: These pharmacological studies suggest that erythromycin prolongs repolarization to a large extent by block of IK. In turn, prolongation of action potential duration resulting from erythromycin's actions on IK may promote the development of EADs. The induction of ventricular arrhythmias observed clinically after exposure to erythromycin may be related to the development of EADs. The rarity of occurrence of ventricular arrhythmias suggests that other predisposing factors contribute to the acquired long QT syndrome associated with erythromycin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8403329     DOI: 10.1161/01.cir.88.4.1832

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  Effects of cytochrome P450 inhibitors on potassium currents and mechanical activity in rat portal vein.

Authors:  G Edwards; P M Zygmunt; E D Högestätt; A H Weston
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

Review 2.  Drug interactions with cisapride: clinical implications.

Authors:  E L Michalets; C R Williams
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

Review 3.  Cardiovascular effects of noncardiovascular drugs.

Authors:  Satish R Raj; C Michael Stein; Pablo J Saavedra; Dan M Roden
Journal:  Circulation       Date:  2009-09-22       Impact factor: 29.690

Review 4.  QT prolongation with antimicrobial agents: understanding the significance.

Authors:  Robert C Owens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 5.  Drug-induced torsade de pointes. Incidence, management and prevention.

Authors:  T S Faber; M Zehender; H Just
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

Review 6.  Torsade de pointes. Mechanisms and management.

Authors:  C Napolitano; S G Priori; P J Schwartz
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 7.  Macrolide antibiotics and the risk of cardiac arrhythmias.

Authors:  Richard K Albert; Joseph L Schuller
Journal:  Am J Respir Crit Care Med       Date:  2014-05-15       Impact factor: 21.405

8.  Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy.

Authors:  Masayuki Nakamori; Katarzyna Taylor; Hideki Mochizuki; Krzysztof Sobczak; Masanori P Takahashi
Journal:  Ann Clin Transl Neurol       Date:  2015-12-10       Impact factor: 4.511

9.  An antibiotic recipe for an arrhythmic disaster.

Authors:  Keir McCutcheon; Pravin Manga
Journal:  Cardiovasc J Afr       Date:  2015 May-Jun       Impact factor: 1.167

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.